Haass lab @Haass_Lab

The Haass lab Twitter account | 🇩🇪 @DZNE_de @SyNergy_Cluster | 🔬AD, FTLD & microglia research | 🕵️ PI Christian Haass (signed -CH) | 💬 Tweets by @LisdeW_ biochemie.abi.med.uni-muenchen.de/index.html DZNE, Munich, Germany Joined March 2021

Tweets

206
Followers

1K
Following

276
Likes

233

Haass lab @Haass_Lab

a year ago

Last post on X: we officially moved to bsky. Come find us there!

0 0 1 211 0

View Details

EU Medicines Agency @EMA_News

2 years ago

📢The CHMP recommends authorising a new treatment for early #AlzheimersDisease in the EU. Leqembi is intended for treatment of mild dementia and cognitive impairment in a restricted patient population with a specific genetic make-up. 👉 ema.europa.eu/en/news/leqemb…

4 38 52 23K 6

View Details

Lena Spieth @LenaSpieth

2 years ago

🚨NEW PAPER ALERT 🚨 Our paper just got published in @ImmunityCP ! From Munich with 🥨 Check it out here: cell.com/immunity/fullt… @Seiji_Kaji, @StefanBerghoff, Mikael Simons #apoe #Alzheimers #microglia 1/9

2 12 45 11K 7

View Details

MatthiasBrendel @matbrendel

2 years ago

🚨 Just out in Theranostics: ☢️ we developed a new microglia specific Cu64-labeled TREM2-PET radiotracer ☢️ importantly this antibody based tracer has an integrated brain shuttle system (hTfR) to cross the blood-brain barrier. thno.org/v14p6319.htm #Theranostics

0 8 30 3K 3

View Details

Helmholtz @helmholtz_de

2 years ago

Wir sprechen in der neuesten Resonator-Podcastfolge über den aktuellen Stand der Alzheimerforschung. Zu Gast ist Christian Haas vom @DZNE_de und es geht auch um neue Medikamente. Ganze Sendung: resonator-podcast.de/2024/res207-zu… #Alzheimer #DZNE #Lecanemab #Podcast

0 3 6 1K 2

View Details

RikOssenkoppele @RikOssenkoppele

2 years ago

Nick Fox making the case that excess brain volume loss associated with Lecanemab (or other effective mAB’s) is associated with the removal of “space-occupying” structures, as amyloid plaques occupy ~6-8% of the cortex in autopsy studies. #AAIC24

5 16 48 5K 10

View Details

Gabor Petzold @Gaborpetzold

2 years ago

Out today, the statement by @DZNE_en experts on the @EMA_News decision on #lecanemab dzne.de/en/im-fokus/me… .

0 4 10 3K 2

View Details

RikOssenkoppele @RikOssenkoppele

2 years ago

Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease Another AD-relevant publication @NEJM this week. TREM2 variants like R47H may induce partial loss of function by interfering with binding of ligands such as low-density lipoprotein (LDL), apolipoprotein E (ApoE), and clusterin (CLU). R47H homozygosity: 1⃣ Does not contribute to Aβ overproduction but instead disrupts Aβ clearance 2⃣ Leads to the accumulation of amyloid plaques 3⃣ Is associated with a high risk of symptomatic Alzheimer’s disease (OR=97.1; 95% CI=23.5-401.1). Conclusion: "The high risk in R47H homozygotes underscores the necessity for early intervention if treatments such as Aβ-removing antibodies are shown to have efficacy at the preclinical stage." Link to paper > nejm.org/doi/pdf/10.105…

0 4 18 3K 6

View Details

Celeste Karch @karchlab

2 years ago

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease nejm.org/doi/full/10.10…

0 7 19 3K 6

View Details

Molecular Neurodegeneration @MolNeuro

2 years ago

'Mis-localization of endogenous #TDP43 leads to #ALS-like early-stage metabolic dysfunction and progressive motor deficits' Yiying Hu, Alexander Hruscha, Chenchen Pan...Bettina Schmid @DZNE_en @SyNergy_Cluster bit.ly/45vRfEk

0 3 7 2K 2

View Details

Hector Fellow Academy @HFA_academy

2 years ago

Big announcement today!📢 We are very pleased to present the new video portrait with Hector Fellow Prof. Dr. Dr. h.c. Christian Haass and his research on Alzheimer's disease.👉youtube.com/watch?v=tHhVov……… #HFA #videoportrait #alzheimersdisease #alzheimersresearch #cellbiology

0 1 5 1K 1

View Details

Dieter Edbauer @dieter_edbauer

2 years ago

Interested in translational science? 🧪 Our team at #DZNE Munich is seeking a technician for the GA-VAX project. Your work could directly contribute to clinical trials with #C9orf72 #ALS patients. Apply now and join our team! #Jobs #Research jobs.dzne.de/de/jobs/101347…

0 7 4 2K 1

View Details

Haass lab @Haass_Lab

2 years ago

In summary, we show that a novel therapeutic approach of single-dose peripheral AAV-induced delivery of a brain penetrant biotherapeutic molecule, can replace PGRN protein levels in the brain and ameliorate disease-relevant phenotypes! (8/8)

0 0 1 366 1

View Details

Haass lab @Haass_Lab

2 years ago

What about a human model system? To assess this we also created a novel human TMEM106B/GRN DKO iPSC model that recapitulates TDP-43 pathology, neurodegeneration and lysosomal abnormalities – all phenotypes can be rescued by treatment with PTV:PGRN (7/8)

1 0 0 470 0

View Details

Haass lab @Haass_Lab

2 years ago

Can we achieve protein replacement in the brain using a single dose gene therapy approach, without infecting the brain? Yes we can! Read it here in our latest paper by @marvin_reich in collaboration with Denali Therapeutics science.org/doi/10.1126/sc… (1/8)